Abstract Details

Title Inpatient Encounter Rates Following Hospitalization for Autoimmune and Viral Encephalitis

Topic Neurohospitalist

Presentation(s) P10 - Poster Session 10 (8:00 AM-9:00 AM)

Poster/Presentation
Number 2-008

Objective To compare short and intermediate-term inpatient encounter rates following hospitalization for autoimmune encephalitis (AE) versus viral encephalitis (VE) using a large multicenter electronic health record database.

Background Autoimmune encephalitis and viral encephalitis are major causes of central nervous system inflammation requiring hospitalization. While their pathophysiology, clinical presentations, and management differ significantly, comparative data on post-hospitalization inpatient healthcare utilization are limited.

Design/Methods Using the TriNetX Network, we identified patients (≥18 years) hospitalized with a first diagnosis of AE (ICD-10: G04.81, G04.89) or VE (A86, B00.4, A85.8, G04.90). Cohorts were defined by the first instance of a qualifying ICD-10 code and an inpatient encounter on the same day. Patients with any occurrence of the opposite diagnosis were excluded. Propensity score matching was performed on age, sex, race, and ethnicity. Outcomes were defined as inpatient encounters occurring within three post-index windows: 1–15 days, 15–30 days, and 30–90 days as a proxy for continued index admission or readmissions following approximated discharge.

Results 7,198 to 8,960 patients were included for each cohort. In the 1-15 day window, AE vs. VE patients had a non-significant difference in inpatient encounter rates (20.4% vs. 21.5%; RR 0.95, 95% CI 0.89–1.006, p=0.08). In the 15–30 day window, AE patients had a significantly increased risk of inpatient encounters (10.4% vs. 9.2%; RR 1.13, 95% CI 1.03–1.24, p=0.011). In the 30–90 day interval, encounter rates were comparable between the groups (13.6% vs. 12.9%; RR 1.06, 95% CI 0.97–1.15, p=0.21).

Conclusions Among matched cohorts, AE was associated with a small but statistically significant increase in inpatient encounters between 15 and 30 days post-hospitalization compared to VE. This window was used as a proxy for readmission following discharge. This may reflect early AE recurrences in patients discharged without bridging immunotherapy. These findings suggest a potential need for intensified follow-up and transitional care strategies for AE patients.

Authors/Disclosures
Sophia F. Damman PRESENTER	Ms. Damman has nothing to disclose.
Ayush Thakur	Mr. Thakur has nothing to disclose.
Isabella G. Shawe	Ms. Shawe has nothing to disclose.
Manisha Ramprasad	Ms. Ramprasad has nothing to disclose.
Hesham A. Abboud, MD (University Hospitals Cleveland Medical Center)	Dr. Abboud has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. The institution of Dr. Abboud has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genentech . Dr. Abboud has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Abboud has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Horizon. Dr. Abboud has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BMS. Dr. Abboud has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alpine Pharma. Dr. Abboud has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Abboud has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon. Dr. Abboud has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Cycle Pharma. Dr. Abboud has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Axonics. Dr. Abboud has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics. Dr. Abboud has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen. Dr. Abboud has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Genentech. Dr. Abboud has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for BMS. Dr. Abboud has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Horizon. Dr. Abboud has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for TG Therapeutics. The institution of Dr. Abboud has received research support from Genentech . The institution of Dr. Abboud has received research support from Novartis. The institution of Dr. Abboud has received research support from BMS. The institution of Dr. Abboud has received research support from Sanofi-Genzyme. The institution of Dr. Abboud has received research support from The Guthy-Jackson Charitable Foundation. The institution of Dr. Abboud has received research support from UCB. Dr. Abboud has received publishing royalties from a publication relating to health care.

��ɫ��

��ɫ��